Parkinson’s disease (PD) treatment is complex; the disease is heterogeneous, requiring individualized treatment and frequent adjustments (e.g., in dosing, in regimens) to achieve symptom control throughout a patient’s disease course. Since 2015, a handful of new therapies that address PD motor and nonmotor symptoms have reached the U.S. market, and a dynamic pipeline comprising a range of therapies designed to optimize levodopa or reduce the frequency and impact of motor response complications could further expand the treatment landscape. As such, understanding the many forces that drive neurologists’ clinical decision making in PD today is crucial for developers of new or newly launched PD therapies facing a complicated market. How PD is treated and the factors behind those treatment decisions in the United States and across the major markets are provided in the Current Treatment Overview. The detailed, expanded analysis in the Current Treatment US content offers deep insights regarding how PD patients are being treated in the United States today, backed by real-world evidence wherever possible.